Enjoy complimentary customisation on priority with our Enterprise License!
Market research analysts at Technavio have predicted that the global asthma therapeutics market will grow steadily over the next four years and post an impressive revenue of more than USD 22 billion by 2020. Owing to the development of target specific drugs, there will be a high demand for monoclonal antibodies for the treatment of asthma. Monoclonal antibodies (mAbs) that block immunoglobulin E and specific cytokines are important in the initiation and persistence of asthmatic inflammation. Xolair was the first mAb to be approved for the treatment of allergic asthma and recorded huge sales right after approval. Since several manufacturers are currently focusing on the development of other mAbs, the forecast period will see the introduction of several new products. And owing to the better efficacy of these drugs over other small molecules, there will be an upsurge in their demand contributing to the growth of the asthma drugs market.
The Americas will account for more than 45% of the total share of the market and dominate the industry during the forecast period. The increase in pollution and the presence of a huge asthmatic population in the Latin American countries are identified to be the major factors that will augment the demand for asthmatic drugs from this region. Also, the introduction of new healthcare reforms of various countries in the region have resulted in reducing the cost of pharmaceutical drugs, providing increased access and quality of healthcare, and offer insurance coverage for individuals of all ages, which will, in turn, fuel the growth of the market in this region.
Owing to the presence of several well established and small scale vendors, this market appears to be highly fragmented. Key players such as GSK, AstraZeneca, Boehringer Ingelheim, F.Hoffmann-La Roche, and Merck have a great product portfolio and account for the major revenue shares. The competition among vendors is intense and the leading vendors have also started acquiring small regional vendors to increase their share of the market. The coming years will witness a number of mergers and acquisitions and innovative product launches, which will further intensify the competitive environment in the market.
The leading vendors in the market are -
The other prominent vendors in the market are ALK-Abello, Amgen, Array BioPharma, Asmacure, Astellas Pharma, Atopix Therapeutics, Axikin Pharmaceuticals, Chiesi Farmaceutici, Dynavax Technologies, Horizon Pharma, Hovione Scientia, Invion, Ivax, Kissei Pharmaceutical, Kyowa Hakko Kirin, MediciNova, Mitsubishi Tanabe Pharma, Mundipharma, Nycomed, Oxagen Limited, Palobiofarma, Pearl Therapeutics, Pharmaking, Pharmaxis, Pulmagen Therapeutics, Regeneron Pharmaceuticals, Revalesio, RSPR Pharma AB, SAMA Pharmaceuticals, Sanofi, Skyepharma, SolAeroMed, Stallergenes, Sterna Biologicals, Synairgen, Theron Pharmaceuticals, UCB Pharma, Vectura, Verona Pharma, and Whanin Pharmaceutical.
During 2015, the preventive medications segment accounted for about 65% of the total market share and dominated this market. These medications are also called controller medications and help in the prevention of asthma attacks on a long-term basis. The continuous use of these medications results in less inflamed airways and controls the chronic symptoms of asthma. As a result, these are an essential treatment for most asthma patients and will have a constant demand in the next four years as well.
Since the onset of action is quick with systemic and local effect by inhalation, this mode of administration will account for major shares of the market and dominate the asthma treatment drugs industry throughout the forecast period. Drug administration by this mode happens in a phased manner, and many of the pipeline products for the treatment of asthma are also being developed for administering via inhalation.
Technavio also offers customization on reports based on specific client requirement.
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: Pipeline portfolio
PART 06: Market landscape
PART 07: Key buying criteria for asthma drugs
PART 08: Market segmentation by type of treatment
PART 09: Market segmentation by drug class
PART 10: Segmentation by route of administration
PART 11: Drug delivery devices market for asthma drugs
PART 12: Geographical segmentation
PART 13: Market drivers
PART 14: Impact of drivers
PART 15: Market challenges
PART 16: Impact of drivers and challenges
PART 17: Market trends
PART 18: Vendor landscape
PART 19: Key vendor analysis
PART 20: Appendix
PART 21: Explore Technavio
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.